Collegium Expands Commercial Organization With Key Appointments

Published 6:30 AM ET Mon, 1 June 2015
Globe Newswire

SHARES

CANTON, Mass., June 1, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the addition of Barry Duke as Executive Vice President and Chief Commercial Officer. In addition to Mr. Duke, Mary Ogle joined as Vice President of Marketing and Timothy Hermes as Vice President of Government Affairs and Alliance Development.

"Barry's deep experience, in both small and large organizations make him a great fit to lead our commercial organization as we prepare for FDA approval and launch of Xtampza ER™." said Michael Heffernan, Chairman and CEO of Collegium.

Mr. Duke brings twenty-five years of commercial experience in specialty and hospital healthcare markets. Prior to joining Collegium, Mr. Duke was Vice President of Sales and Marketing – U.S. Biosurgery at Sanofi, Inc. (formerly Genzyme Corporation). Over the course of his career, Mr. Duke also held positions at Enzon Pharmaceuticals, Inc., The Liposome Company, Inc., Astra USA, Inc., Centocor, Inc. and The Upjohn Company.

Ms. Ogle joined Collegium from Purdue Pharma L.P. where she led all aspects of Marketing and Managed Markets for the company, including the recent launch of Hysingla ER (hydrocodone bitartrate). Prior to joining Purdue, Ms. Ogle was Vice President, Global Strategic Marketing for the Global Specialty Medicines Group at Teva Pharmaceuticals, Inc. Ms. Ogle also held positions at Sanofi-Aventis and Johnson & Johnson.

Mr. Hermes brings extensive Government Affairs and Alliance Development experience to the Collegium. His prior experience includes senior government affairs roles at Auxilium Pharmaceuticals, Inc. and Sepracor Inc.

In addition, Mary Theriault had previously joined Collegium as Senior Director of Commercial Operations from Precision Dermatology Inc. and Mark Semiao joined as Regional Director from Zogenix, Inc. where he launched Zohydro ER.

"I look forward to working with the Collegium team as we build the commercial infrastructure to support a commercial launch of Xtampza ER after FDA approval." said Barry Duke. "The commercial team will also benefit from a diverse mix of deep pain experience combined with significant commercial launch experience in multiple therapeutic areas."

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. The new drug application, or NDA, filing for Xtampza, the Company's lead product candidate, was accepted by the FDA on February 10, 2015. The FDA set a Prescription Drug User Fee Act, or PDUFA, goal date of October 12, 2015 for completion of its review of the Xtampza NDA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that we will obtain approval for Xtampza or any of our other product candidates from the U.S. Food and Drug Administration ("FDA") or foreign regulatory authorities; even if Xtampza is approved, we may not be able to obtain the label claims that we are seeking from the FDA. Furthermore, we are subject to patent infringement litigation relating to Xtampza and may, in the future, be subject to additional litigation relating to our other product candidates, which may be expensive to defend and delay the commercialization of Xtampza or our other product candidates. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: our ability to commercialize our product candidates; the size and growth potential of the markets for our product candidates, and our ability to service those markets; our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of our product candidates; the success, cost and timing of our product development activities, studies and clinical trials; the success of competing products that are or become available; and our expectations regarding our ability to obtain and adequately maintain sufficient intellectual property protection for our product candidates. These and other risks are described under the heading "Risk Factors" in the registration statement on Form S-1 (commission file number 333-203208), which was declared effective by the Securities and Exchange Commission ("SEC") on May 6, 2015. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.